

ASX:NRT  
NASDAQ:NVGN

Novogen Ltd  
(Company)

ABN 37 063 259 754

---

### Capital Structure

Ordinary Shares on  
issue:

423 M

---

### Board of Directors

**Ian Phillips**  
Interim Chairman

**Steve Coffey**  
Non-Executive Director

**John O'Connor**  
Non-Executive Director

**Prof Peter Gunning**  
Non-Executive Director

**Bryce Carmine**  
Non-Executive Director

**ASX RELEASE**  
22 July 2015

## RESIGNATION OF CEO

The Board of Directors of Novogen Limited (the **Board**) wishes to advise that it has accepted the resignation of its Chief Executive Officer and Director, Dr Graham Kelly, effective today

Dr Kelly has decided to leave the Company to resume his work in non-oncology based early stage research. During his time as Chairman of the Board and Chief Executive Officer, Dr Kelly has shown great commitment and energy in ensuring that Novogen is in a sound financial position with three drug candidates on track to enter Phase 1 clinical trials in 2016/17.


Dr Kelly said, "I am satisfied that I am leaving the Company in a very sound position. The Company is well placed now to proceed into the clinic with its 3 oncology drug candidates. It doesn't require me to steer it from here. My particular interest and skills are in early-stage drug development, and I now want to focus on that."

The Board wishes Dr Kelly well in his future endeavours.

An announcement regarding the steps that Novogen will take to fill this role will be made in the near future.

### About Novogen

Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms (the super-benzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that are first-in-class with potential application across a range of cancers. Given the encouraging data from in vitro and in vivo pre-clinical Proof-of-Concept studies in the field of Oncology, our immediate focus is to bring our lead Oncology drug candidates Cantrixil, Anisina and Trilexium into the clinic in 2016 pending successful completion of their respective toxicology programs. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural



cancers (glioblastoma, neuroblastoma in children) and melanoma are the potential clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to therapy.

For more information, please visit [www.novogen.com](http://www.novogen.com)

**Media Enquiries**

Kym Robins

Marketing and Communications Manager

Novogen Group

E: [Kym.Robins@novogen.com](mailto:Kym.Robins@novogen.com)

+61 (0) 2 9472 4109

